Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accounts Payables (2016 - 2025)

Avalo Therapeutics' Accounts Payables history spans 12 years, with the latest figure at $137000.0 for Q4 2025.

  • For Q4 2025, Accounts Payables fell 51.59% year-over-year to $137000.0; the TTM value through Dec 2025 reached $137000.0, down 51.59%, while the annual FY2025 figure was $137000.0, 51.59% down from the prior year.
  • Accounts Payables reached $137000.0 in Q4 2025 per AVTX's latest filing, down from $474000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.9 million in Q1 2021 to a low of $137000.0 in Q4 2025.
  • Average Accounts Payables over 5 years is $2.4 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: surged 337.01% in 2021, then plummeted 84.52% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $3.4 million in 2021, then decreased by 14.46% to $2.9 million in 2022, then crashed by 84.52% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then tumbled by 51.59% to $137000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Accounts Payables are $137000.0 (Q4 2025), $474000.0 (Q3 2025), and $2.4 million (Q2 2025).